Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

41. Pro-/synbiotic treatment and postoperative function, complications and quality of life in colorectal cancer: a systematic review and meta-analysis

Pro-/synbiotic treatment and postoperative function, complications and quality of life in colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

42. Concurrent systematic chemotherapy and molecular targeted therapy for unresectable metastatic colorectal cancer : a systematic review

Concurrent systematic chemotherapy and molecular targeted therapy for unresectable metastatic colorectal cancer : a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

43. Components of the full blood count (FBC) as risk factors for colorectal cancer detection: a systematic review

Components of the full blood count (FBC) as risk factors for colorectal cancer detection: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

44. The prognostic value of CRY1/2 in colorectal cancer: a systematic review and meta-analysis

The prognostic value of CRY1/2 in colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

45. The potentials of N-Myc Downstream-Regulated Gene 2 (NDRG2) as a predictive biomarker for colorectal cancer: a systematic review and meta-analysis

The potentials of N-Myc Downstream-Regulated Gene 2 (NDRG2) as a predictive biomarker for colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

46. The use of simulation modeling to inform health system and policy decision-making in colorectal cancer (CRC) screening delivery: a systematic review

The use of simulation modeling to inform health system and policy decision-making in colorectal cancer (CRC) screening delivery: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

47. Impact of dietary fiber on colorectal cancer among adults

Impact of dietary fiber on colorectal cancer among adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

48. Imaging modalities for the prediction of complete pathological response of colorectal cancer liver metastasis after chemotherapy

Imaging modalities for the prediction of complete pathological response of colorectal cancer liver metastasis after chemotherapy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

49. FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab in therapy for metastatic colorectal cancer: a systematic review and meta-analysis

FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab in therapy for metastatic colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

50. Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer

Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

51. Prescription of 5-fluorouracil/capecitabine versus S-1 and adverse drug events among colorectal cancer patients: a systematic review and meta-analysis

Prescription of 5-fluorouracil/capecitabine versus S-1 and adverse drug events among colorectal cancer patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

52. Laparoscopic versus open resection for colorectal cancer and long-term non-oncological outcomes: a meta-analysis of randomized and non-randomized trials

Laparoscopic versus open resection for colorectal cancer and long-term non-oncological outcomes: a meta-analysis of randomized and non-randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

53. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial

Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screenings for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs (...) diagnosed with CRC 30 days or longer after screening (interval cancer group, n = 163) and individuals diagnosed with CRC in the nonscreened group (controls, n = 1740). All CRCs in the control group were identified when they developed symptoms (clinically detected CRCs). Analyses were stratified by cancer site. We used Cox regression to estimate hazard ratio (HRs), adjusted for age and sex.Over the follow-up period, 43 individuals in the interval cancer group died from CRC; among controls, 525 died from

2019 EvidenceUpdates

54. A systematic review of the association between BMI and colorectal cancer in younger population

A systematic review of the association between BMI and colorectal cancer in younger population Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

55. Biliary drainage for malignant biliary obstruction due to metastatic colorectal cancer: a systematic review

Biliary drainage for malignant biliary obstruction due to metastatic colorectal cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

56. The effect of laxative use on colorectal cancer risk: a systematic review and meta-analysis

The effect of laxative use on colorectal cancer risk: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

57. What risk is carried and what are the consequences of dehydration or renal impairment following defunctioning ileostomy in patients undergoing major resection for colorectal cancer?

What risk is carried and what are the consequences of dehydration or renal impairment following defunctioning ileostomy in patients undergoing major resection for colorectal cancer? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

58. Polygenic risk prediction models for colorectal cancer: a systematic review

Polygenic risk prediction models for colorectal cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

59. Proportions of unexplained versus explained mismatch repair deficient colorectal cancers: a meta-analysis

Proportions of unexplained versus explained mismatch repair deficient colorectal cancers: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

60. Efficacy and safety of bevacizumab plus irinotecan-based or oxaliplatin-based regimens as first-line treatment for metastatic colorectal cancer: a systematic review and meta-analysis

Efficacy and safety of bevacizumab plus irinotecan-based or oxaliplatin-based regimens as first-line treatment for metastatic colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO